EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Marinomed Biotech AG's Enterprise Value is €28.84 Mil.
Marinomed Biotech AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.10 Mil. Therefore, Marinomed Biotech AG's EV-to-FCF for today is -26.22.
The historical rank and industry rank for Marinomed Biotech AG's EV-to-FCF or its related term are showing as below:
FRA:93Z'
s EV-to-FCF Range Over the Past 10 Years
Min: -41.61 Med: -17.01 Max: -6.69
Current: -26.22
During the past 11 years, the highest EV-to-FCF of Marinomed Biotech AG was -6.69. The lowest was -41.61. And the median was -17.01.
FRA:93Z's EV-to-FCF is ranked worse than 100% of 336
companies
in the Biotechnology industry
Industry Median: 14.7
vs FRA:93Z: -26.22
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Marinomed Biotech AG (FRA:93Z) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Marinomed Biotech AG's PE Ratio (TTM) for today is calculated as:
Marinomed Biotech AG's share price for today is €8.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Marinomed Biotech AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €10.148.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Marinomed Biotech AG EV-to-FCF Related Terms
Marinomed Biotech AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Marinomed Biotech AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Marinomed Biotech AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marinomed Biotech AG EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Marinomed Biotech AG's EV-to-FCF falls into.
Marinomed Biotech AG's current Enterprise Value is €28.84 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Marinomed Biotech AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marinomed Biotech AG (FRA:93Z) has a EV-to-FCF of -26.22 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Marinomed Biotech AG and its competitors. According to the industry distribution chart, Marinomed Biotech AG ranks #999999 out of 336 companies in the Biotechnology industry.
Is Marinomed Biotech AG's EV-to-FCF too high?
Marinomed Biotech AG's current EV-to-FCF is -26.22. Based on the distribution chart, Marinomed Biotech AG ranks #999999 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marinomed Biotech AG has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marinomed Biotech AG ranks #999999 out of 336 companies for EV-to-FCF. This places Marinomed Biotech AG in the lower half of its industry. The industry median EV-to-FCF is 14.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Marinomed Biotech AG and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marinomed Biotech AG's current EV-to-FCF is -26.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (FRA:93Z) is currently considered Possible Value Trap. The stock's GF Value™ is €17.68, compared to a current price of €8.80 — trading 50.2% below its estimated fair value. The current EV-to-FCF is -26.22. Marinomed Biotech AG's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Marinomed Biotech AG (FRA:93Z), the current EV-to-FCF is -26.22 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Marinomed Biotech AG (FRA:93Z) Overvalued in 2026?
Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued.
The current stock price of €8.80 is trading 50.2% below its estimated GF Value™ of €17.68.
GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.
Key valuation signals for FRA:93Z:
EV-to-FCF: -26.22
GF Value™: €17.68 vs. price of €8.80 (50.2% below fair value)
No single metric tells the full story. See the FRA:93Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
46GF Score
Get the complete analysis for FRA:93Z
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:93Z has been successfully added to your 
